Skip Nav Destination
Issues
1 February 2012
-
Cover Image
Cover Image
McKie and colleagues show that OPCML expression is silenced in multiple tumor types, including the vast majority of high-grade serous ovarian tumors, and correlates with poor prognosis. They further establish an extracellular mechanism of OPCML-mediated tumor suppression through negative regulation of a specific group of receptor tyrosine kinases (RTK). Through binding to RTK extracellular domains, OPCML induces RTK membrane redistribution, internalization, and degradation. Recombinant OPCML downregulated the same RTKs in vivo and inhibited ovarian cancer cell growth, suggesting that extracellular protein therapy may be useful in the treatment of OPCML-deficient tumors. For details, please see the article by McKie and colleagues on page 156. - PDF Icon PDF LinkTable of Contents
ISSN 2159-8274
EISSN 2159-8290
In This Issue
In the Spotlight
Prospective
Research Briefs
Inherited Variation at Chromosome 12p13.33, Including RAD52, Influences the Risk of Squamous Cell Lung Carcinoma
Jianxin Shi; Nilanjan Chatterjee; Melissa Rotunno; Yufei Wang; Angela C. Pesatori; Dario Consonni; Peng Li; William Wheeler; Peter Broderick; Marc Henrion; Timothy Eisen; Zhaoming Wang; Wei Chen; Qiong Dong; Demetrius Albanes; Michael Thun; Margaret R. Spitz; Pier Alberto Bertazzi; Neil E. Caporaso; Stephen J. Chanock; Christopher I. Amos; Richard S. Houlston; Maria Teresa Landi
Research Articles
The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer
Arthur B. McKie; Sebastian Vaughan; Elisa Zanini; Imoh S. Okon; Louay Louis; Camila de Sousa; Mark I. Greene; Qiang Wang; Roshan Agarwal; Dmitry Shaposhnikov; Joshua L. C. Wong; Hatice Gungor; Szymon Janczar; Mona El-Bahrawy; Eric W-F. Lam; Naomi E. Chayen; Hani Gabra
Essential Gene Profiles in Breast, Pancreatic, and Ovarian Cancer Cells
Richard Marcotte; Kevin R. Brown; Fernando Suarez; Azin Sayad; Konstantina Karamboulas; Paul M. Krzyzanowski; Fabrice Sircoulomb; Mauricio Medrano; Yaroslav Fedyshyn; Judice L.Y. Koh; Dewald van Dyk; Bohdana Fedyshyn; Marianna Luhova; Glauber C. Brito; Franco J. Vizeacoumar; Frederick S. Vizeacoumar; Alessandro Datti; Dahlia Kasimer; Alla Buzina; Patricia Mero; Christine Misquitta; Josee Normand; Maliha Haider; Troy Ketela; Jeffrey L. Wrana; Robert Rottapel; Benjamin G. Neel; Jason Moffat
News in Brief
News in Depth
Research Watch
Breast Cancer
Cell Death
Chemotherapy
Clinical Trials
Drug Resistance
Glioma
Immune Evasion
Lung Cancer
Ovarian Cancer
Prostate Cancer
Retinoblastoma
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.